Technology area: Biotechnology & Pharmaceuticals
68 pending office actions • 41 clients • 63 examiners • 36 art units • 0 of 68 (0%) have an AI response strategy ready
McNeill PLLC focuses on Biotechnology & Pharmaceuticals and has handled 1,957 career applications. Its profile lists 69 pending office actions and a 70.36% resolved allowance rate.
The average of 3.62 office actions per allowance indicates recurring prosecution activity before allowance. The combination of the resolved rate and the pending docket gives practitioners a basis for evaluating both historical outcomes and the need for continued examination management.
Based on the USPTO statutory response window for each pending office action. 18 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 18 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 10 (15%) |
| §103 only | 13 (19%) |
| §112 only | 7 (10%) |
| Double-patenting only | 2 (3%) |
| Double-patenting + other | 15 (22%) |
| Multi-statute (no §101) | 20 (29%) |
| No statute on record | 1 (1%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HASAN, KHALEDA B | 2 | 59.3% | +49.0% |
| SPENCE, JENNIFER SUZANNE | 2 | 66.9% | +46.0% |
| DEVI, SARVAMANGALA | 2 | 65.5% | +55.5% |
| HASTINGS, ALISON AZAR | 2 | 62.5% | +42.1% |
| HIBBERT, CATHERINE S | 2 | 58.8% | +48.6% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.2% |
| FAN, WEIHUA | 1 | 83.3% | +12.7% |
| PACKARD, BENJAMIN J | 1 | 66.9% | +15.3% |
| KENYON, JOHN S | 1 | 79.7% | +18.2% |
| IBRAHIM, MEDINA AHMED | 1 | 87.4% | +12.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19276658 | Stabilized Nucleic Acids Encoding Messenger Ribonucleic Acid (mRNA) | FAN, WEIHUA | — |
| 18955685 | Methods for Preparing Mutant Plants | IBRAHIM, MEDINA AHMED | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18248079 | CD19-Directed Chimeric Antigen Receptor Constructs | HAMA, JOANNE | 104d overdue |
| 17836265 | Modified Guide RNAs for Gene Editing | ARIETI, RUTH SOPHIA | 30d overdue |
| 17921128 | Glucocorticoid Receptor (GR) Modulators for Treating a SARS-COV-2 Virus | HAVLIN, ROBERT H | 23d overdue |
| 17637410 | BLOOD GENE BIOMARKERS TO DIAGNOSE AND PREDICT ACUTE REJECTION IN LIVER TRANSPLANT RECIPIENTS | MYERS, CARLA J | 2d overdue |
| 18844546 | Modulation of Protein Levels | KEOGH, MATTHEW R | 60d |
| 19571722 | Lamotrigine Salts, Co-Crystals, and Compositions | CHANDRAKUMAR, NIZAL S | — |
| 19100872 | Reduction of Signs of Skin Aging | PACKARD, BENJAMIN J | — |
| 18881324 | Oral Liposomal Formulations of Fasudil | KENYON, JOHN S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19630254 | Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding Agent | HASAN, KHALEDA B | — |
| 19571722 | Lamotrigine Salts, Co-Crystals, and Compositions | CHANDRAKUMAR, NIZAL S | — |
| 19276658 | Stabilized Nucleic Acids Encoding Messenger Ribonucleic Acid (mRNA) | FAN, WEIHUA | — |
| 19100872 | Reduction of Signs of Skin Aging | PACKARD, BENJAMIN J | — |
| 18881324 | Oral Liposomal Formulations of Fasudil | KENYON, JOHN S | — |
| 18955685 | Methods for Preparing Mutant Plants | IBRAHIM, MEDINA AHMED | — |
| 18929289 | CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof | SPENCE, JENNIFER SUZANNE | — |
| 18904985 | Materials and Methods for Treatment of Hemoglobinopathies | SPENCE, JENNIFER SUZANNE | — |
| Art Unit | Apps |
|---|---|
| 1625 | 4 |
| 1633 | 4 |
| 1627 | 4 |
| 1682 | 4 |
| 1636 | 3 |
| 1663 | 3 |
| 1612 | 3 |
| 1645 | 3 |
| 1675 | 3 |
| 1631 | 3 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19630254 | Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding Agent | Intellia Therapeutics, Inc. | HASAN, KHALEDA B | 1636 | §103DP | Non-Final OA | — | Pending | Mar 26, 2026 |
| 19571722 | Lamotrigine Salts, Co-Crystals, and Compositions | Azurity Pharmaceuticals Ireland Limited | CHANDRAKUMAR, NIZAL S | 1625 | §103§112Other | Final Rejection | — | Pending | Mar 19, 2026 |
| 19276658 | Stabilized Nucleic Acids Encoding Messenger Ribonucleic Acid (mRNA) | Intellia Therapeutics, Inc. | FAN, WEIHUA | 1663 | DP | Non-Final OA | — | Pending | Jul 22, 2025 |
| 19100872 | Reduction of Signs of Skin Aging | Carbocode S.A. | PACKARD, BENJAMIN J | 1612 | §101§102§112DP | Non-Final OA | — | Pending | Feb 03, 2025 |
| 18881324 | Oral Liposomal Formulations of Fasudil | Woolsey Pharmaceuticals, Inc. | KENYON, JOHN S | 1625 | §102§103§112 | Non-Final OA | — | Pending | Jan 06, 2025 |
| 18955685 | Methods for Preparing Mutant Plants | Carlsberg A/S | IBRAHIM, MEDINA AHMED | 1662 | §112Other | Non-Final OA | — | Pending | Nov 21, 2024 |
| 18929289 | CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof | Vertex Pharmaceuticals Incorporated | SPENCE, JENNIFER SUZANNE | §103§112Other | Non-Final OA | — | Pending | Oct 28, 2024 | |
| 18924880 | Abuse-Deterrent Pharmaceutical Composition with Aversion Properties | Aardvark Therapeutics Inc. | AGGARWAL, SAHIL CHANDER | 1623 | §102§103§112 | Non-Final OA | — | Pending | Oct 23, 2024 |
| 18904985 | Materials and Methods for Treatment of Hemoglobinopathies | Vertex Pharmaceuticals Incorporated | SPENCE, JENNIFER SUZANNE | 1633 | §102§103§112DP | Non-Final OA | — | Pending | Oct 02, 2024 |
| 18850107 | Novel Salt of GLP-1 Receptor Agonist Compound, Preparation Method Thereof and Pharmaceutical Composition Comprising Thereof | Ildong Pharmaceutical Co., Ltd. | HUI, SAN MING R | 1627 | §103 | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18844546 | Modulation of Protein Levels | Carlsberg A/S | KEOGH, MATTHEW R | 1663 | §102§103 | Final Rejection | 60d | Pending | Sep 06, 2024 |
| 18792984 | CD33-Binding Polypeptides and Uses Thereof | Inhibrx Biosciences, Inc. | ROONEY, NORA MAUREEN | 1641 | §112Other | Non-Final OA | — | Pending | Aug 02, 2024 |
| 18782817 | Method for Using Gene Expression to Determine Prognosis of Prostate Cancer | Mdxhealth SA | HANEY, AMANDA MARIE | 1682 | §101§103§112 | Non-Final OA | — | Pending | Jul 24, 2024 |
| 18728193 | DETECTION AND LOCALIZATION OF INTERNAL BLEEDING | Cumberland Emerging Technologies, Inc. | LEWOCZKO, EVAN MICHAEL | 1612 | §103 | Non-Final OA | — | Pending | Jul 11, 2024 |
| 18724529 | Altering the Optical Properties of Fibres | Commonwealth Scientific And Industrial Research Organisation | KRUSE, DAVID H | 1663 | §102§103§112 | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18739986 | AAV Vectors | Vigeneron GmbH | BLUMEL, BENJAMIN P | 1671 | §112 | Final Rejection | — | Pending | Jun 11, 2024 |
| 18716404 | Uses of Bicyclic Compounds for the Treatment of Diseases | Leonabio, Inc. | COPPINS, JANET L | 1628 | §103§112DP | Non-Final OA | — | Pending | Jun 04, 2024 |
| 18710370 | Formulations and Methods for Treating Symptoms of Menopause | Kindra Corporation | OLSON, ANDREA STEFFEL | 1693 | §102§103§112DP | Non-Final OA | — | Pending | May 15, 2024 |
| 18640699 | Parabacteroides Goldsteinii to Treat or Prevent Inflammatory and AutoImmune Diseases | Joslin Diabetes Center | DEVI, SARVAMANGALA | 1645 | §102§112 | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18702733 | CONDITION-ACTIVATABLE NUCLEIC ACID CONSTRUCTS AND THEIR USES FOR TREATING NEUROLOGICAL DISEASES | Switch Therapeutics Inc. | YU, DAVID TUYANG | 1635 | §103§112DP | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18631587 | Monohydrate Salt of Denatonium Acetate | Aardvark Therapeutics, Inc. | OH, TAYLOR V | 1625 | §102§103 | Final Rejection | — | Pending | Apr 10, 2024 |
| 18611364 | ST2 ANTIGEN BINDING PROTEINS | Amgen, Inc. | MCCOLLUM, ANDREA K | 1674 | §101§112Other | Non-Final OA | — | Pending | Mar 20, 2024 |
| 18606338 | Methods of Using Donor-Derived Cell-Free DNA to Distinguish Acute Rejection and Other Conditions in Liver Transplant Recipients | Northwestern University | SWITZER, JULIET CAROLINE | 1682 | §101§102§103§112 | Final Rejection | — | Pending | Mar 15, 2024 |
| 18683006 | 2,4-Dihydro-3H-1,2,4-Triazol-3-One P2X7 Antagonists | Breye Therapeutics Aps | HASTINGS, ALISON AZAR | 1627 | §103§112 | Final Rejection | — | Pending | Feb 12, 2024 |
| 18435117 | Compounds and Compositions for Selective Degradation of Engineered Proteins | Bristol-Myers Squibb Company | ISMAIL, REHANA | 1625 | §102§103§112 | Non-Final OA | — | Pending | Feb 07, 2024 |
| 18434621 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR PROTEINS | Rayzebio, Inc. | MOSHER, ERIC PARKER | 1612 | §101§102§103§112DP | Non-Final OA | — | Pending | Feb 06, 2024 |
| 18431646 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR KRAS G12C PROTEINS | Rayzebio, Inc. | MEJIAS, SAMANTHA LEE | 1618 | §103§112 | Non-Final OA | — | Pending | Feb 02, 2024 |
| 18431656 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR PROTEINS | Rayzebio, Inc. | DONOHUE, SEAN R | 1618 | §102§103DP | Non-Final OA | — | Pending | Feb 02, 2024 |
| 18423804 | Methods, Systems, and Compositions for Diagnosing Transplant Rejection | The Scripps Research Institute | JONES, CHRISTINE MICHELLE | 1682 | §101§103§112DP | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18579943 | Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disorders | Tim Therapeutics, Inc. | PIPIC, ALMA | 1617 | §103 | Final Rejection | 53d | Pending | Jan 17, 2024 |
| 18577414 | Fetal Mesenchymal Stem Cells | Boost Pharma Aps | WESTON, ALYSSA G | 1633 | §101§102§103 | Final Rejection | — | Pending | Jan 08, 2024 |
| 18513964 | Methods for Reducing Risk of Onset of Acute Graft Versus Host Disease After Hematopoeitic Cell Transplantation | Csl Behring LLC | BEANE, RANDALL L | 1654 | §103 | Final Rejection | 70d | Pending | Nov 20, 2023 |
| 18511869 | USE OF HER2-TARGETING ANTIBODY-DRUG CONJUGATE IN TREATMENT OF HER2-LOW EXPRESSING BREAST CANCER | Remegen Co., Ltd. | BUCCINI, MICHELLE CALLAHAN | 1675 | §103§112DP | Non-Final OA | — | Pending | Nov 16, 2023 |
| 18510979 | Therapeutic Microvesicles of Probiotic Bacteria | BIOGAIA AB | HINES, JANA A | 1645 | §103 | Non-Final OA | — | Pending | Nov 16, 2023 |
| 18507778 | Compositions and Methods for Targeting Cancer Stem Cells | The General Hospital Corporation | COOK, LISA V | 1642 | §103§112DP | Non-Final OA | — | Pending | Nov 13, 2023 |
| 18557182 | COMBINATION OF BITTER RECEPTOR AGONIST AND GUT-SIGNALING COMPOUND | Aardvark Therapeutics, Inc. | HIBBERT, CATHERINE S | 1658 | §102§103§112 | Non-Final OA | — | Pending | Oct 25, 2023 |
| 18279612 | Compositions and Methods For Reducing Immune Intolerance | Tim Therapeutics, Inc. | KIM, YUNSOO | 1641 | §112Other | Non-Final OA | — | Pending | Aug 31, 2023 |
| 18456269 | Compositions and Methods for Treatment of Myotonic Dystrophy Type 1 with CRISPR/SACAS9 | Vertex Pharmaceuticals Incorporated | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §103§112Other | Non-Final OA | — | Pending | Aug 25, 2023 |
| 18450966 | USE OF ANTIBODY-DRUG CONJUGATE TARGETING HER2 IN TREATMENT OF SPECIFIC BREAST CANCER | Remegen Co., Ltd. | PUTTLITZ, KARL J | 1646 | §103DP | Final Rejection | — | Pending | Aug 16, 2023 |
| 18546155 | Methods for Treating Multiple Myeloma | Celgene Corporation | BENAVIDES, JENNIFER ANN | 1675 | §101§103 | Non-Final OA | — | Pending | Aug 11, 2023 |
| 18264475 | Formulations of DR5 Binding Polypeptides | Inhibrx Biosciences, Inc. | CESARE, JOSEPH DAVID | 1675 | §112Other | Non-Final OA | 5d | Pending | Aug 07, 2023 |
| 18275254 | Danegaptide for Use in the Treatment or Prevention of a Kidney Disease | Breye Therapeutics Aps | MCMILLIAN, KARA RENITA | 1623 | §103 | Final Rejection | — | Pending | Aug 01, 2023 |
| 18339930 | Compositions and Methods for Genetically Modifying CIITA in a Cell | Intellia Therapeutics, Inc. | SMALL, KATHERINE R | 1633 | §102§112 | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18339665 | Compositions and Methods for Reducing HLA-A in a Cell | Intellia Therapeutics, Inc. | SPENCER, ANDREA LYNNE MORRIS | 1631 | §103§112 | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18332335 | Polynucleotides, Compositions, and Methods for Genome Editing Involving Deamination | Intellia Therapeutics, Inc. | REGA, KYLE THOMAS | 1636 | §102§103§112 | Non-Final OA | — | Pending | Jun 09, 2023 |
| 18332390 | Compositions and Methods for Reducing MHC Class II in a Cell | Intellia Therapeutics, Inc. | KIM, TAEYOON | 1631 | §102§103§112 | Non-Final OA | — | Pending | Jun 09, 2023 |
| 18265063 | Aldehyde Dehydrogenase Inhibitors and Their Therapeutic Use | Cancer Research Technology Limited | HASTINGS, ALISON AZAR | 1627 | §103 | Non-Final OA | — | Pending | Jun 02, 2023 |
| 18323488 | Methods and Treatment for Complex Lymphatic Malformations | Avalo, Inc. | KOSTURKO, GEORGE W | 1621 | §103 | Final Rejection | 49d overdue | Pending | May 25, 2023 |
| 18253485 | Method for Treating Antibody-Mediated Rejection | Csl Behring GmbH | HIBBERT, CATHERINE S | 1658 | §103§112DP | Final Rejection | — | Pending | May 18, 2023 |
| 18248079 | CD19-Directed Chimeric Antigen Receptor Constructs | Sorrento Therapeutics, Inc. | HAMA, JOANNE | 1647 | §103§112 | Final Rejection | 104d overdue | Pending | Apr 06, 2023 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial70.4% of resolved applications prosecuted by Mcneill Pllc were allowed, across 1,957 applications in USPTO records.
3.62 office actions per allowed application on average.
68 pending office actions as of October 2026, for 41 clients, before 63 examiners in 36 art units.
